Compare Abeona Therapeutics Inc (ABEO) vs Crown Castle International Corp (CCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Crown Castle International Corp — how do they compare? Abeona Therapeutics Inc trades at $7.51 (market cap $421.19M), while Crown Castle International Corp trades at $73.93 (market cap $31.33B). The key difference: Crown Castle International Corp is far larger — about 74.4× Abeona Therapeutics Inc's market cap, and Crown Castle International Corp pays a 5.77% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | CCI | |
|---|---|---|
Market Cap | $421.19M | $31.33B |
Sector | Health | Real Estate |
52-Week High | $7.45 | $103.79 |
52-Week Low | $4.17 | $73.61 |
Enterprise Value | $276.10M | $53.69B |
Dividend Yield | — | 5.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
Crown Castle (CCI) trades at $74.06, up 0.61% today, near a one-year low. The stock shows a bearish technical trend but maintains a 5.5% dividend yield. Recent Q2 2026 earnings beat AFFO estimates, with organic growth of 3.9%, though revenue declined year-over-year. The company completed its transition to a pure-play U.S. tower operator after selling its fiber business.
Outlook is mixed: analyst consensus is split evenly between Buy and Hold with a $95.29 price target, suggesting 29% upside. Key risks include high debt levels (debt-to-asset ratio of 77.21% in 2025) and competitive pressure in the tower REIT sector. The current valuation appears discounted relative to historical multiples, offering potential for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →
